Limb Girdle Muscular Dystrophy is a diverse group of disorders with many subtypes categorized by disease gene and inheritance. LGMD usually manifests in the proximal muscles around the hips and shoulders. (The proximal muscles are those closest to the center of the body; distal muscles are farther away from the center — for example, in the hands and feet).
- According to a study conducted by Wang et. al. (2018), LGMD is the fourth most common muscular dystrophy, with a pooled prevalence of 1.63 per 100,000 people, following myotonic dystrophy, dystrophinopathy, and facioscapulohumeral dystrophy. The prevalence varies among subtypes and regions.
- Overall, onset is more common in childhood but it may even occur late in adult life. LGMD2A (calpain-deficient LGMD; calpainopathy) usually affects children between the ages of 8-15, but may range from 2-40 years of age. LGMD2J (titinopathy) occurs when two titin gene mutations are present and has a variable age of onset ranging from 10-30 years.
DelveInsight's "Limb Girdle Muscular Dystrophy (LGMD) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Limb Girdle Muscular Dystrophy (LGMD) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Limb Girdle Muscular Dystrophy (LGMD) Market Growth
The Limb Girdle Muscular Dystrophy (LGMD) market size shall grow during the forecast period owing to the increasing Prevalence of Limb Girdle Muscular Dystrophy (LGMD) in the 7MM.
The Limb Girdle Muscular Dystrophy (LGMD) market analysis section of the report helps to understand the current and forecasted Limb Girdle Muscular Dystrophy (LGMD) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Limb Girdle Muscular Dystrophy (LGMD) market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Limb Girdle Muscular Dystrophy (LGMD) Therapeutics Market
The management of limb-girdle muscular dystrophy (LGMD) is supportive; no disease-modifying treatments are available. Treatment is aimed at the specific symptoms present in each individual. Specific treatment options may include physical and occupational therapy to improve muscle strength and prevent contractures; the use of various devices to assist with walking (ambulation) and mobility; surgery to correct skeletal abnormalities; and regular monitoring of the heart and the respiratory system for the development of such complications potentially associated with some forms of LGMD.
The dynamics of Limb Girdle Muscular Dystrophy (LGMD) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period.
Limb Girdle Muscular Dystrophy (LGMD) Companies involved in developing therapies include ML Bio Solutions, Sarepta Therapeutics, Catabasis Pharmaceuticals, aTyr Pharma, and many others. Limb Girdle Muscular Dystrophy (LGMD) Therapies covered in the report include BBP-418, SRP-9003, CAT-1004, ATYR1940, SRP-9005, and many more.
Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Forecast
The Limb Girdle Muscular Dystrophy (LGMD) epidemiology section covers insights about historical and current Limb Girdle Muscular Dystrophy (LGMD) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Segmentation
- Total prevalent Cases of Limb Girdle Muscular Dystrophy (LGMD)
- Type-specific prevalent Cases of Limb Girdle Muscular Dystrophy (LGMD)
- Gender-specific prevalent Cases of Limb Girdle Muscular Dystrophy (LGMD)
- Diagnosed and Treatable cases of Limb Girdle Muscular Dystrophy (LGMD)
It helps to recognize the causes of current and forecasted Limb Girdle Muscular Dystrophy (LGMD) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
For more details, visit: Limb Girdle Muscular Dystrophy (LGMD) Market Growth